Welcome to the Executive Edge.
This week’s newsletter is 1,262 words (an 8 min read)
An at-a-glance view of Medicare prescription drug negotiations
What could be expected from the FTC under Andrew Ferguson
An evaluation of KFF predictions about the second Trump administration
- Ava and the Industry Insights and Advisory Team
Overview of Topics:
Uncertainty Surrounds Drug Pricing Policies Due to Change in Administration: President Trump’s recent executive order rescinding some IRA-based initiatives has caused uncertainty over the future of the Medicare Drug Price Negotiation Program. The fledgling program had yet to rollout its first round of negotiated drug prices, which would have produced significant savings for Medicare beneficiaries.
Will New FTC Chair Defrost Healthcare M&A?: Andrew Ferguson’s appointment as FTC chair under the Trump administration signals a likely shift toward merger-friendly policy that may result in reduced antitrust scrutiny. Ferguson is likely to repeal certain merger restrictions, which may accelerate healthcare M&A approvals.
Comparing KFF policy predictions to January 20th executive orders: A report by KFF detailed possible healthcare policies that could be impacted by Trump administration initiatives. In light of the executive orders signed by President Trump on January 20th, many of KFF’s predictions rang true, especially those relating to the Affordable Care Act, Medicaid, LGBTQ+ healthcare, and Global Health.